Nicola Silvestris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1348118/publications.pdf

Version: 2024-02-01

287	7,357	53794	114465
papers	citations	45 h-index	63 g-index

309	309	309	11527
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer, 2005, 103, 994-999.	4.1	186
2	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. Journal of Experimental and Clinical Cancer Research, 2020, 39, 95.	8.6	147
3	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Scientific Reports, 2019, 9, 4099.	3.3	112
4	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077.	1.2	108
5	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treatment Reviews, 2010, 36, S56-S61.	7.7	103
6	Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Annals of Translational Medicine, 2020, 8, 482-482.	1.7	101
7	Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 2020, 12, 1047.	3.7	95
8	Dasatinib: An Anti-Tumour Agent via Src Inhibition. Current Drug Targets, 2011, 12, 563-578.	2.1	93
9	Hospital Admission of Cancer Patients: Avoidable Practice or Necessary Care?. PLoS ONE, 2015, 10, e0120827.	2.5	93
10	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget, 2016, 7, 67142-67149.	1.8	91
11	The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine and Growth Factor Reviews, 2018, 39, 46-61.	7.2	90
12	Expression and prognostic value of VEGFR-2, PDGFR-Î², and c-Met in advanced hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2013, 32, 16.	8.6	86
13	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
14	High density of tryptaseâ€positive mast cells in human colorectal cancer: a poor prognostic factor related to proteaseâ€activated receptor 2 expression. Journal of Cellular and Molecular Medicine, 2013, 17, 1025-1037.	3.6	80
15	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	1.8	77
16	Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget, 2016, 7, 58649-58658.	1.8	76
17	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114.	2.8	76
18	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. Digestive and Liver Disease, 2016, 48, 231-241.	0.9	74

#	Article	IF	Citations
19	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330.	3.7	71
20	Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study. Frontiers in Genetics, 2020, 11, 641.	2.3	71
21	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	6.4	69
22	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biology and Therapy, 2016, 17, 400-406.	3.4	67
23	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 4427.	4.1	67
24	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. PLoS ONE, 2013, 8, e83026.	2.5	66
25	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	1.8	66
26	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942.	3.7	66
27	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget, 2015, 6, 23323-23341.	1.8	65
28	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	8.6	65
29	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 2021, 9, 532.	4.4	65
30	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. Critical Reviews in Oncology/Hematology, 2015, 95, 46-61.	4.4	64
31	Role of MicroRNA in Response to Ionizing Radiations: Evidences and Potential Impact on Clinical Practice for Radiotherapy. Molecules, 2014, 19, 5379-5401.	3.8	63
32	Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. International Journal of Molecular Sciences, 2013, 14, 19731-19762.	4.1	59
33	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. Expert Opinion on Therapeutic Targets, 2015, 19, 1623-1635.	3.4	58
34	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. International Journal of Molecular Sciences, 2020, 21, 8305.	4.1	58
35	Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers, 2021, 13, 2414.	3.7	58
36	Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Supportive Care in Cancer, 2013, 21, 1313-1319.	2.2	57

#	Article	IF	Citations
37	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2013, 8, e74402.	2.5	56
38	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules, 2014, 19, 6393-6406.	3.8	56
39	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines, 2021, 9, 373.	3.2	55
40	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Molecular Oncology, 2013, 7, 308-322.	4.6	54
41	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of Experimental and Clinical Cancer Research, 2015, 34, 156.	8.6	54
42	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers, 2019, 11, 1419.	3.7	54
43	Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. Diagnostics, 2020, 10, 704.	2.6	54
44	Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Lithuania), 2019, 55, 707.	2.0	53
45	Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget, 2017, 8, 33897-33910.	1.8	50
46	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. Oncology, 2009, 77, 57-68.	1.9	49
47	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. Journal of Clinical Medicine, 2020, 9, 1594.	2.4	49
48	Role of gemcitabine in metastatic breast cancer patients: A short review. Breast, 2008, 17, 220-226.	2.2	47
49	Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. Molecules, 2014, 19, 2458-2468.	3.8	47
50	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. International Journal of Molecular Sciences, 2017, 18, 418.	4.1	47
51	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines, 2021, 9, 1075.	3.2	46
52	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
53	The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Annals of Oncology, 2009, 20, 941-945.	1.2	45
54	Coâ€expression of CD133⁺/CD44⁺ in human colon cancer and liver metastasis. Journal of Cellular Physiology, 2013, 228, 408-415.	4.1	45

#	Article	IF	Citations
55	Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers. Translational Oncology, 2018, 11, 825-835.	3.7	45
56	Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. Cancers, 2019, 11, 113.	3.7	45
57	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers, 2019, 11, 539.	3.7	45
58	Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety, 2015, 14, 253-267.	2.4	43
59	Target Therapies in Pancreatic Carcinoma. Current Medicinal Chemistry, 2014, 21, 948-965.	2.4	43
60	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	3.9	42
61	EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1962.	3.0	42
62	Cancer survivorship. Current Opinion in Oncology, 2015, 27, 351-357.	2.4	41
63	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. International Journal of Molecular Sciences, 2020, 21, 3054.	4.1	41
64	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. Clinical and Experimental Medicine, 2022, 22, 65-74.	3.6	41
65	Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype. Experimental and Molecular Pathology, 2012, 92, 296-303.	2.1	40
66	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 552.	2.4	40
67	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2021, 165, 103436.	4.4	40
68	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Annals of Oncology, 2010, 21, 1565.	1.2	38
69	COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. Frontiers in Oncology, 2020, 10, 734.	2.8	38
70	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine and Pharmacotherapy, 2022, 146, 112516.	5.6	38
71	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Translational Oncology, 2019, 12, 585-595.	3.7	36
72	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. European Journal of Cancer, 2019, 111, 94-106.	2.8	36

#	Article	IF	Citations
73	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. International Journal of Molecular Sciences, 2021, 22, 10719.	4.1	36
74	Current status of targeted therapies in advanced gastric cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S29-S34.	3.4	35
75	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	4.4	35
76	MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. International Journal of Molecular Sciences, 2020, 21, 2578.	4.1	35
77	A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. Genes, 2021, 12, 1206.	2.4	35
78	Takotsubo Syndrome in a Patient Treated With Sunitinib for Renal Cancer. Journal of Clinical Oncology, 2012, 30, e218-e220.	1.6	34
79	Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy. Journal of Clinical Medicine, 2021, 10, 1051.	2.4	34
80	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
81	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	3.1	33
82	Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. European Journal of Clinical Investigation, 2019, 49, e13087.	3.4	33
83	IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. International Journal of Clinical and Laboratory Research, 1997, 27, 48-54.	1.0	32
84	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	5.3	32
85	The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Frontiers in Immunology, 2021, 12, 676181.	4.8	32
86	From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy. Molecules, 2021, 26, 2278.	3.8	31
87	TremelImumab and Durvalumab Combination for the Non-Operatlve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 2021, 13, 2839.	3.7	31
88	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports, 2017, 7, 42499.	3.3	30
89	Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. Clinical and Experimental Medicine, 2018, 18, 319-323.	3.6	30
90	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. International Journal of Molecular Sciences, 2020, 21, 5034.	4.1	30

#	Article	IF	Citations
91	PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomedicine and Pharmacotherapy, 2021, 138, 111436.	5.6	30
92	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. Journal of Clinical Medicine, 2021, 10, 3567.	2.4	30
93	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	1.8	29
94	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. Pancreas, 2018, 47, 759-771.	1.1	29
95	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
96	Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). Annals of Oncology, 2014, 25, 1243-1247.	1.2	28
97	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2017, 111, 152-165.	4.4	28
98	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opinion on Biological Therapy, 2015, 15, 155-162.	3.1	27
99	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	3.7	27
100	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the SocietÃ Italiana di Nefrologia (SIN). ESMO Open, 2017, 2, e000167.	4.5	27
101	Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers, 2019, 11, 1718.	3.7	27
102	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1â€“infected Patients. Journal of Experimental Medicine, 1996, 184, 2287-2300.	8.5	26
103	Challenges and Opportunities of MicroRNAs in Lymphomas. Molecules, 2014, 19, 14723-14781.	3.8	26
104	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	4.4	26
105	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers, 2020, 12, 1729.	3.7	26
106	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget, 2016, 7, 15243-15251.	1.8	26
107	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2022, 169, 103567.	4.4	26
108	The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomedicine and Pharmacotherapy, 2022, 148, 112735.	5.6	26

#	Article	IF	Citations
109	Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clinical and Experimental Immunology, 1998, 114, 179-188.	2.6	25
110	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers, 2019, 11, 1270.	3.7	25
111	Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sciences, 2021, 282, 119826.	4.3	25
112	Identification of early diagnostic biomarkers via WGCNA in gastric cancer. Biomedicine and Pharmacotherapy, 2022, 145, 112477.	5.6	25
113	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Oncologist, 2016, 21, 600-607.	3.7	24
114	miR-34a and miR-200c Have an Additive Tumor-Suppressive Effect on Breast Cancer Cells and Patient Prognosis. Genes, 2021, 12, 267.	2.4	24
115	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 795-803.	3.6	23
116	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.9	23
117	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. Acta OncolÃ³gica, 2003, 42, 693-700.	1.8	22
118	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific Reports, 2016, 6, 24136.	3.3	22
119	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.7	22
120	From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past. Frontiers in Immunology, 2021, 12, 623639.	4.8	22
121	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 2021, 12, 704110.	4.8	22
122	Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer. Oncology, 2005, 69, 273-282.	1.9	21
123	Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Supportive Care in Cancer, 2011, 19, 1823-1830.	2.2	21
124	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Critical Reviews in Oncology/Hematology, 2013, 85, 112-120.	4.4	21
125	The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomedicine and Pharmacotherapy, 2021, 137, 111364.	5.6	21
126	A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. Biomedicine and Pharmacotherapy, 2021, 143, 112213.	5.6	21

#	Article	IF	Citations
127	Oncosuppressor methylation: A possible key role in colon metastatic progression. Journal of Cellular Physiology, 2011, 226, 1934-1939.	4.1	20
128	CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. International Journal of Molecular Sciences, 2014, 15, 15767-15777.	4.1	20
129	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers, 2020, 12, 1681.	3.7	20
130	Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study. Journal of Medical Internet Research, 2020, 22, e19152.	4.3	20
131	A Phase I Study of Capecitabine in Combination with Vinorelbine in Advanced Breast Cancer. Clinical Breast Cancer, 2003, 4, 138-141.	2.4	19
132	NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1587.	2.8	19
133	Angiogenesis in adenosquamous cancer of pancreas. Oncotarget, 2017, 8, 95773-95779.	1.8	19
134	Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis. Biomedicine and Pharmacotherapy, 2022, 146, 112537.	5.6	19
135	Synthetic Lethality to Overcome Cancer Drug Resistance. Current Medicinal Chemistry, 2012, 19, 3858-3873.	2.4	18
136	Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (United States), 2016, 95, e3273.	1.0	18
137	Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. Journal of Experimental and Clinical Cancer Research, 2017, 36, 128.	8.6	18
138	The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy. Current Drug Metabolism, 2011, 12, 713-721.	1.2	17
139	Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0235887.	2.5	17
140	MicroRNAs and lncRNAsâ€"A New Layer of Myeloid-Derived Suppressor Cells Regulation. Frontiers in Immunology, 2020, 11, 572323.	4.8	17
141	Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147, 3177-3188.	5.1	17
142	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	4.4	17
143	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2022, 173, 103674.	4.4	17
144	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. Oncology, 2009, 77, 69-74.	1.9	16

#	Article	IF	Citations
145	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dellâ€™Italia Meridionale Multicenter Phase II Study. Oncology, 2010, 79, 415-422.	1.9	16
146	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 96.	8.6	16
147	Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treatment Reviews, 2010, 36, S46-S55.	7.7	15
148	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 453-461.	3.4	15
149	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	3.6	15
150	The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors. Expert Review of Molecular Diagnostics, 2015, 15, 979-987.	3.1	14
151	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	3.6	14
152	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori, 2018, 104, 476-479.	1.1	14
153	Varied functions of immune checkpoints during cancer metastasis. Cancer Immunology, Immunotherapy, 2021, 70, 569-588.	4.2	14
154	A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. International Journal of Molecular Sciences, 2021, 22, 10389.	4.1	14
155	The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy. Biomedicine and Pharmacotherapy, 2022, 146, 112588.	5.6	14
156	Adjuvant Therapy in Colon Cancer. Oncology, 2009, 77, 50-56.	1.9	13
157	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opinion on Therapeutic Targets, 2012, 16, S111-S117.	3.4	13
158	Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?. Cancers, 2019, 11, 1393.	3.7	13
159	Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	7.0	13
160	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/SocietÃ Italiana Endocrinologia (SIE)/SocietÃ Italiana Farmacologia (SIF) multidisciplinary consensus position paper. ESMO Open, 2021, 6, 100153.	4.5	13
161	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1Î±â€”Final results of the ALICE-2 study.. Journal of Clinical Oncology, 2016, 34, 280-280.	1.6	13
162	Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1367-1383.	3.0	13

#	Article	IF	Citations
163	PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opinion on Therapeutic Targets, 2021, 25, 1007-1016.	3.4	13
164	p53 as the main traffic controller of the cell signaling network. Frontiers in Bioscience - Landmark, 2010, 15, 1172.	3.0	12
165	Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?. Supportive Care in Cancer, 2014, 22, 2813-2819.	2.2	12
166	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. Cancer Biology and Therapy, 2015, 16, 1140-1147.	3.4	12
167	Independent Negative Prognostic Role of TCF1 Expression within the Wnt/Î²-Catenin Signaling Pathway in Primary Breast Cancer Patients. Cancers, 2019, 11, 1035.	3.7	12
168	COVID-19 Pandemic and the Crisis of Health Systems: The Experience of the Apulia Cancer Network and of the Comprehensive Cancer Center Istituto Tumori â€œGiovanni Paolo Iiâ€•of Bari. International Journal of Environmental Research and Public Health, 2020, 17, 2763.	2.6	12
169	Robotic radiosurgery in pancreatic cancer: A systematic review. World Journal of Gastroenterology, 2015, 21, 9420.	3.3	12
170	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1261-1268.	2.8	12
171	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2022, 169, 103572.	4.4	12
172	Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. Cancers, 2022, 14, 5.	3.7	12
173	Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. Breast, 2010, 19, 214-218.	2.2	11
174	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. Current Drug Metabolism, 2011, 12, 918-931.	1.2	11
175	mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma. Current Medicinal Chemistry, 2012, 19, 945-954.	2.4	11
176	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	2.8	11
177	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	1.9	11
178	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societaâ€™ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2019, 140, 39-51.	4.4	11
179	The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review. International Journal of Molecular Sciences, 2021, 22, 2652.	4.1	11
180	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget, 2017, 8, 66699-66708.	1.8	11

#	Article	IF	Citations
181	KRASmutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. Expert Opinion on Biological Therapy, 2009, 9, 565-577.	3.1	10
182	Advances in EGFR-directed therapy in head and neck cancer. Frontiers in Bioscience - Scholar, 2011, S3, 454-466.	2.1	10
183	Antineoplastic drug-induced bradyarrhythmias. Expert Opinion on Drug Safety, 2012, 11, 739-751.	2.4	10
184	Combined modality treatments in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S71-S81.	3.4	10
185	Targeting TGF-Î²-Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from Naja naja oxiana Venom in Melanoma. Molecules, 2020, 25, 5148.	3.8	10
186	Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomedicine and Pharmacotherapy, 2022, 145, 112370.	5.6	10
187	Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. Biomedicine and Pharmacotherapy, 2022, 146, 112558.	5.6	10
188	The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme. Frontiers in Oncology, 2022, 12, 818447.	2.8	10
189	Unique Case of Giant Adult Paratesticular Spindle Cell Rhabdomyosarcoma. Urology, 2009, 73, 500-502.	1.0	9
190	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 4681-4686.	2.0	9
191	A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?. Journal of Experimental and Clinical Cancer Research, 2020, 39, 109.	8.6	9
192	A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead. Frontiers in Oncology, 2021, 11, 689839.	2.8	9
193	The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 722833.	2.8	9
194	Genomic characterization of hepatoid tumors: context matters. Human Pathology, 2021, 118, 30-41.	2.0	9
195	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. Oncotarget, 2017, 8, 50845-50863.	1.8	9
196	Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. British Journal of Cancer, 2003, 88, 491-495.	6.4	8
197	Synchronous Presentation of B-Cell Chronic Lymphocytic Leukemia/Small-Cell Lymphoma and Colon Adenocarcinoma Within the Same Mesenteric Lymph Nodes and a Single Liver Metastasis. Journal of Clinical Oncology, 2011, 29, e11-e13.	1.6	8
198	Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opinion on Therapeutic Targets, 2012, 16, S83-S89.	3.4	8

#	Article	IF	Citations
199	Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Supportive Care in Cancer, 2013, 21, 2955-2956.	2.2	8
200	Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists. PLoS ONE, 2014, 9, e101170.	2.5	8
201	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6287.	3.3	8
202	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	2.4	8
203	Unusual Response to Second-Line Single-Agent Gemcitabine in Locally Advanced Primary Leiomyosarcoma of the Lung: A Case Report. Journal of Chemotherapy, 2003, 15, 507-509.	1.5	7
204	Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 2011, S3, 16-22.	2.1	7
205	The Italian Rare Pancreatic Exocrine Cancer Initiative. Tumori, 2019, 105, 353-358.	1.1	7
206	Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Letters, 2019, 445, 1-10.	7.2	7
207	Bioinformatics-Based Identification of a circRNA-miRNA-mRNA Axis in Esophageal Squamous Cell Carcinomas. Journal of Oncology, 2020, 2020, 1-9.	1.3	7
208	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/SocietÃ Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2020, 154, 103066.	4.4	7
209	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. Frontiers in Oncology, 2020, 10, 572329.	2.8	7
210	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1973.	3.0	7
211	Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study. Biomedicine and Pharmacotherapy, 2022, 147, 112691.	5.6	7
212	Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer. Annals of Oncology, 2002, 13, 1862-1867.	1.2	6
213	Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma. Tumori, 2005, 91, 103-103.	1.1	6
214	Peripheral Skin Edema as Unusual Toxicity in Three Patients with Advanced Non-small Cell Lung Cancer Treated with Pemetrexed Alone or in Combination with Cisplatin. Journal of Thoracic Oncology, 2011, 6, 1964.	1.1	6
215	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Journal of Geriatric Oncology, 2019, 10, 591-597.	1.0	6
216	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. Journal of Gastrointestinal Cancer, 2022, 53, 289-298.	1.3	6

#	Article	IF	Citations
217	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. Cancers, 2021, 13, 1906.	3.7	6
218	Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?. Molecules, 2021, 26, 6877.	3.8	6
219	â€œPureâ€•hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 41-47.	2.8	6
220	Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis. Frontiers in Genetics, 2022, 13, 848646.	2.3	6
221	Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103657.	4.4	6
222	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. Human Pathology, 2022, 128, 124-133.	2.0	6
223	Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis. Clinical and Experimental Medicine, 2001, 1, 127-132.	3.6	5
224	Synchronous Mandibular and Giant Parieto-occipital Skull Metastasis From Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, A26.	4.4	5
225	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. Cancer Biology and Therapy, 2013, 14, 467-468.	3.4	5
226	Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomarkers, 2014, 14, 151-162.	1.7	5
227	Metastatic gastric cancer in the last two decades: goals achieved and future promises. Future Oncology, 2015, 11, 2633-2636.	2.4	5
228	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. Expert Review of Gastroenterology and Hepatology, 2018, 12, 471-478.	3.0	5
229	Bone metastases in biliary cancers: A multicenter retrospective survey. Journal of Bone Oncology, 2018, 12, 33-37.	2.4	5
230	Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer. International Journal of Biological Macromolecules, 2020, 162, 1283-1292.	7.5	5
231	The role of letrozole (Femara(R)) in breast cancer therapy: A clinical review. Drugs of Today, 2001, 37, 639.	1.1	5
232	Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies. Current Drug Targets, 2009, 10, 982-1000.	2.1	5
233	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. Frontiers in Immunology, 2021, 12, 788211.	4.8	5
234	Breast Cancer Metastatic to the Choroid in a Male Patient Case Report. Tumori, 2003, 89, 333-335.	1.1	4

#	Article	IF	Citations
235	TORCH Study: How Much Longer Should We Continue to Use Erlotinib in Unselected Patients With Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2013, 31, 288-289.	1.6	4
236	Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori, 2013, 99, e241-e244.	1.1	4
237	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics, 2014, 15, 1701-1715.	1.3	4
238	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1189.	3.7	4
239	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 2019, 11, 749.	3.7	4
240	Hydroxy-Propil-Î²-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4
241	The Role of Laparoscopic Surgery in Localized Pancreatic Neuroendocrine Tumours. Current Treatment Options in Oncology, 2021, 22, 27.	3.0	4
242	A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. Frontiers in Immunology, 2021, 12, 734956.	4.8	4
243	Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype. Oncotarget, 2017, 8, 87782-87794.	1.8	4
244	Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma. Anticancer Research, 2009, 29, 675-6.	1.1	4
245	On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. Frontiers in Oncology, 2020, 10, 1340.	2.8	3
246	Silencing ZEB2 Induces Apoptosis and Reduces Viability in Glioblastoma Cell Lines. Molecules, 2021, 26, 901.	3.8	3
247	Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test. Diagnostics, 2021, 11, 975.	2.6	3
248	Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncology Letters, 2020, 20, 2469-2476.	1.8	3
249	A Promising Role of TGF-Î² Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. Medicina (Lithuania), 2021, 57, 1241.	2.0	3
250	Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?. Future Oncology, 2013, 9, 1809-1811.	2.4	2
251	Complete Response to Second Line Paclitaxel Every 2 Weeks of Eyelid Kaposi Sarcoma. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, e114-e115.	0.8	2
252	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. Annals of Oncology, 2014, 25, 2443-2444.	1.2	2

#	Article	IF	Citations
253	Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. Frontiers in Oncology, 2020, 10, 1292.	2.8	2
254	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Acta OncolÃ³gica, 2021, 60, 1317-1324.	1.8	2
255	Hepatocellular Cancer. UNIPA Springer Series, 2021, , 689-706.	0.1	2
256	Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol. Frontiers in Oncology, 0, 12, .	2.8	2
257	Rapidly Progressive Coma in Leptomeningeal Carcinomatosis From Undiagnosed Bronchioloalveolar Carcinoma. Journal of Clinical Oncology, 2009, 27, e65-e66.	1.6	1
258	P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. Annals of Oncology, 2015, 26, iv32.	1.2	1
259	Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. Annals of Oncology, 2017, 28, vi48.	1.2	1
260	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. Journal of Chemotherapy, 2022, 34, 123-132.	1.5	1
261	Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial. Oncology Reports, 0, , .	2.6	1
262	What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?. EBioMedicine, 2021, 74, 103733.	6.1	1
263	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. Journal of Chemotherapy, 2022, 34, 543-549.	1.5	1
264	Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. Molecules, 2022, 27, 3545.	3.8	1
265	Importance of paraneoplastic papulosquamous disorders in patients with solid tumors. Journal of Chemotherapy, 1999, 11, 237-238.	1.5	0
266	Long-Term Follow-Up in Breast Cancer Survivors: A Single Institution Survey. Journal of Women's Health, 2003, 12, 599-600.	3.3	0
267	Giant Borderline Phyllodes Tumor of the Breast. Breast Journal, 2008, 14, 203-204.	1.0	0
268	Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. Expert Opinion on Therapeutic Targets, 2013, 17, 473-475.	3.4	0
269	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. Tumori, 2014, 100, e309-e313.	1.1	0
270	Editorial (Thematic Issue: Targeted Therapies in Upper Gastrointestinal Malignancies). Current Medicinal Chemistry, 2014, 21, 947-947.	2.4	0

#	Article	IF	Citations
271	Does First-Line Therapy Affect the Outcome of Patients with Pancreatic Cancer?. Annals of Oncology, 2014, 25, iv236.	1.2	0
272	MiRNAs modulate gastric cancer drug response by affecting hypoxia signaling. Annals of Oncology, 2015, 26, vi99.	1.2	0
273	In Reply. Oncologist, 2016, 21, e5-e6.	3.7	0
274	Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, e42.	0.9	0
275	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Annals of Oncology, 2017, 28, vi45.	1.2	0
276	CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). Annals of Oncology, 2018, 29, viii477-viii478.	1.2	0
277	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations. Annals of Oncology, 2018, 29, viii261-viii262.	1.2	0
278	The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. Annals of Oncology, 2018, 29, viii264.	1.2	0
279	Focus on pancreatic cancer. Digestive and Liver Disease, 2018, 50, 1272-1273.	0.9	0
280	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. Annals of Oncology, 2019, 30, iv57.	1.2	0
281	THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. Journal of Hepatology, 2019, 70, e356.	3.7	0
282	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	1.3	0
283	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2015, 33, e15156-e15156.	1.6	0
284	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15126-e15126.	1.6	0
285	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. Journal of Clinical Oncology, 2016, 34, e15553-e15553.	1.6	0
286	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study.. Journal of Clinical Oncology, 2017, 35, e15684-e15684.	1.6	0
287	Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare. Frontiers in Oncology, 2022, 12, 859903.	2.8	0